Interpretable machine learning for low-sample multi-omics: a case study of ferret vaccine response
Nehleh Kargarfard1, Robert Dunne2, Carol Lee1
1Australian e-Health Research Centre, Commonwealth Scientific and Industrial Research Organisation, Sydney, NSW 2145, Australia.
Bioinformatics Advances
|July 1, 2026
Summary
Interpretable machine learning (IML) models successfully identified key molecular markers predicting vaccine response in ferrets. This approach offers transparent insights into complex biological systems, enhancing vaccine development.
Area of Science:
- Computational Biology
- Systems Biology
- Immunology
Background:
- Machine learning models are crucial for biological pathway analysis but often lack interpretability.
- Interpretable machine learning (IML) aims to bridge the gap between predictive accuracy and biological understanding.
Purpose of the Study:
- To apply an IML framework to multi-omics data for identifying molecular signatures of vaccine response.
- To demonstrate that IML can provide biologically meaningful insights without compromising predictive performance.
Main Methods:
- Utilized an IML framework combining TreeFARMS and Rashomon Set analysis on ferret multi-omics data (transcriptomics, proteomics, lipidomics, metabolomics).
- Generated sparse, interpretable decision trees optimized for accuracy and compactness.
- Identified stable and alternative molecular rules predictive of vaccination status.
Main Results:
- The IML models outperformed ensemble methods in predicting vaccination status.
- Concise if-then rules linked specific molecular features (e.g., AZGP1 expression, ketoleucine levels) to immune response patterns.
- Successfully captured biologically meaningful signatures of vaccine response.
Conclusions:
- IML provides a transparent and reproducible alternative to black-box models in multi-omics analysis.
- This proof-of-concept demonstrates the utility of IML for uncovering mechanisms of vaccine response.
- The developed framework can enhance understanding of complex biological systems and accelerate vaccine development.

